Stage (next event)

Expected Date

Phase 1 Readout

Q1 2021

Catalyst Info & Data Links

Mechanism of Action


By utilizing the Company’s proprietary intranasal vaccine technology, it is expected that AdCOVID has the potential to activate multiple arms of the immune system as shown in a recent Phase 2 clinical study with NasoVAX, an influenza vaccine candidate based on the same platform technology. That study showed potent stimulation of mucosal and cellular immune responses in addition to a strong serum antibody response.

Updated by MV

Prior Data (click to view full image)


Trial Design / Revenue (click to view full image)


Recent Posts

See what the community is saying - click to see full post

Merck acuires Arqule: Non-covalent Btk kinase inhibitors take center stage

AMRN - Near-Term Price Acton Depends on Breadth of Label, but Acquisition Chatter and Quarterly Resu

ITCI - Investors Should Proceed with Caution with Imminent Phase 3 Readouts & FDA Decision In Co

CARA Reports Success in Kidney Disease Itching

FDA Decision on Heron's Non-Opioid Pain Med Imminent

Amp Core Q2 '19 Report

*Disclaimer: Information provided on and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon